Significant Agreements (Details) $ in Thousands		3 Months Ended		6 Months Ended
	Sep. 26, 2022 USD ($) treatment	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Emergent | TEMBEXA | Base Period
Schedule of Investments
Up-front cash payment	$ 238,000
Quantity royalty rate, trigger (treatments) | treatment	1,700,000
Emergent | TEMBEXA | Base Period | Non- United States
Schedule of Investments
Gross profit royalty rate (as a percent)	15.00%
Emergent | TEMBEXA | Base Period | United States
Schedule of Investments
Gross profit royalty rate (as a percent)	20.00%
Emergent | BARDA | Base Period
Schedule of Investments
Maximum milestone proceeds upon the exercise of options	$ 124,000
SymBio Pharmaceuticals | Scenario, Plan
Schedule of Investments
Deferred revenue	$ 12,500
Emergent Biodefense Operations Lansing LLC
Schedule of Investments
Revenue recognized		$ 0	$ 26	$ 0	$ 200
Ohara Pharmaceutical Co., Ltd.
Schedule of Investments
License agreement, nonrefundable regulatory milestone payment to be received							$ 2,500
CR Sanjui | Oncoceutics, Inc.
Schedule of Investments
Payment to be received upon achievement of milestones						$ 5,000